Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable biotech stocks to invest in now. On August 18, Morgan Stanley raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $80 from$75, keeping an Overweight rating on the shares. Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now? The firm told investors in a research note that the EPS 2025 guidance for Halozyme Therapeutics, Inc. (NASDAQ:HALO) has increased by 20% since January, f ...